Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cediranib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 0.87 |
| ▸ | FLT1 known ✓ | P17948 | 5/20 | 0.87 |
| ▸ | FLT4 known ✓ | P35916 | 5/20 | 0.87 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.87 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.87 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 4/20 | 0.87 |
| ▸ | PLK4 | O00444 | 1/20 | 0.87 |
| ▸ | GAK | O14976 | 1/20 | 0.87 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | ERN1 | O75460 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.87 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.87 |
| ▸ | LCK | P06239 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cediranib SCHEMBL1218429 | 1.00 | KDR (0.87) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL1218427 | 1.00 | KDR (0.87) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29351942 | 1.00 | KDR (0.87) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL63147 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29383181 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29351458 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| Cediranib SCHEMBL29368143 | 0.93 | KDR (1.00) | KDRFLT1FLT4RETPLK4 | |
| SCHEMBL1685423 | 0.92 | ABCB11 (1.00) | KDRFLT1FLT4RETPLK4 | |
| SCHEMBL1401646 | 0.88 | KDR (0.81) | KDRFLT1FLT4RETPLK4 | |
| SCHEMBL297569 | 0.88 | KDR (0.81) | KDRFLT1FLT4RETPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4071174-B1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | ASTRAZENECA AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4071174-A1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | AstraZeneca AB (SE) | 2022-10-12 | — | — | EP | disclosed |
| EP-3417294-B1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | ASTRAZENECA AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-20210322415-A1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | ASTRAZENECA AB (SE) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322415-A1 | METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB | FLT1, FLT4, KDR | KDR 3/4885FLT1 1/4885FLT4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.